Summary
The therapeutic efficacy and tolerability of enprostil at a dosage of 35μg twice daily were compared with the efficacy and tolerability of ranitidine 150mg twice daily in the short term treatment of benign gastric ulcer in a double-blind controlled trial in 43 patients. The healing efficacy of enprostil was not significantly different from that of ranitidine. By week 4 of treatment, the healing rates were 41% (7 of 17 patients) for enprostil and 50% (11 of 22 patients) for ranitidine, and at 8 weeks, 77% (10 of 13 patients) and 91% (20 of 22 patients), respectively. Enprostil was shown to be less efficacious than ranitidiné in controlling ulcer symptoms, and its use was associated with a higher incidence of mild adverse reactions, all gastrointestinal.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bardhan KD, Walker PR, Hinchcliffe RFC Gastric ulcer healing: a comparison of enprostil versus ranitidine. Journal of Clinical Gastroenterology 13: 157–162, 1991
Bianchi Porro G, Parente F. Prostaglandins as treatment for peptic ulcer: an overview of worldwide clinical experience. In Bianchi Porro & Dajani (Eds) Gastrointestinal cytoprotection by Prostaglandins. Focus on misoprostol, pp. 39–46, Cortina International, Verona, 1987
Bianchi Porro G, Parente F. Side-effects of anti-ulcer Prostaglandins: an overview of the worldwide experience. Scandinavian Journal of Gastroenterology 24 (Suppl. 164): 224–231, 1989
Bianchi Porro G, Parente F. Site- and cyto-protective drugs in the short-term treatment of peptic ulcer. What is their current role? Italian Journal of Gastroenterology 22 (Suppl. 1): 5–10, 1990
Cohen MM, McCready DR, Clark L, Sevelius H. Protection against aspirin-induced antral and duodenal damage with enprostil: a double-blind endoscopic study. Gastroenterology 88: 286–382, 1985
Dammann HG, Huttemann W, Kalek HD, Rohner HG, Simon B. Comparative trial of enprostil and ranitidine in the treatment of gastric ulcer. American Journal of Medicine 81: 80–84, 1986
Deakin M, Ramage JK, Paul A, Gray S, Billings J, et al. Effect of enprostil on 24-hour intragastric acidity and nocturnal acid and pepsin output. Gut 26A: 545, 1985
Garay GL, Roszkowski AP, Carter H, Annesley P, Waites AA, et al. Enprostil, a synthetic anti-ulcer Prostaglandin has a long duration of action and prevents erosive gastric damage in arthritic rats (abstr). Gastroenterology 86: 1085, 1984
Hawkey CJ, Simpson G, Somerville KW. Reduction by enprostil of aspirin-induced blood loss from human gastric mucosa. American Journal of Medicine 81 (Suppl. 2A): 50–53, 1986
Mahachai V, Walker K, Sevelius H, Thomson ABR. Antisecretory and serum gastrin lowering effect of enprostil in patients with duodenal ulcer disease. Gastroenterology 89: 555–561, 1985
Morgan AG, Pacsoo C, Taylor P, McAdam WAF. A comparison between enprostil and ranitidine in the management of gastric ulceration. Alimentary Pharmacology and Therapeutics 4: 635–641, 1990
Penston JG, Wormsley KG. Histamine H2-receptor antagonists versus Prostaglandins in the treatment of peptic ulcer disease. Drugs 37: 391–401, 1989
Richardson CT. Gastriculcer. In Sleisenger & Fordtran (Eds) Gastrointestinal disease. Pathophysiology, diagnosis, management, pp. 879–909, Saunders, Philadelphia, 1989
Thomas FJ, Koss MA, Hogan DL, Isenberg JI. Enprostil, a synthetic Prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer. American Journal of Medicine 81 (Suppl. 2A): 44–49, 1986
Unge P, Almstrom C, Carling L, Cronstedt J, Ekstrom P, et al. A comparison of enprostil and Cimetidine in the treatment of gastric ulcer. Digestive Diseases and Sciences 31: 211s, 1986
Watebury LD, Mahoney JM, Garay JL. Effects of enprostil, an anti-ulcer Prostaglandin on gastric mucus secretion. American Journal of Medicine 81 (Suppl. 2A): 30–33, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bianchi Porro, G., Parente, F., Lazzaroni, M. et al. Enprostil vs Ranitidine in the Short Term Treatment of Benign Gastric Ulcer. Drug Invest 4, 143–148 (1992). https://doi.org/10.1007/BF03258392
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258392